IBDEI1F7 ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,22975,1,3,0)
 ;;=3^Purpura,Hemorrhagic Condition
 ;;^UTILITY(U,$J,358.3,22975,1,4,0)
 ;;=4^D69.8
 ;;^UTILITY(U,$J,358.3,22975,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,22976,0)
 ;;=L08.9^^76^992^28
 ;;^UTILITY(U,$J,358.3,22976,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22976,1,3,0)
 ;;=3^Pyoderma
 ;;^UTILITY(U,$J,358.3,22976,1,4,0)
 ;;=4^L08.9
 ;;^UTILITY(U,$J,358.3,22976,2)
 ;;=^5009082
 ;;^UTILITY(U,$J,358.3,22977,0)
 ;;=L01.00^^76^992^29
 ;;^UTILITY(U,$J,358.3,22977,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22977,1,3,0)
 ;;=3^Impetigo
 ;;^UTILITY(U,$J,358.3,22977,1,4,0)
 ;;=4^L01.00
 ;;^UTILITY(U,$J,358.3,22977,2)
 ;;=^5008938
 ;;^UTILITY(U,$J,358.3,22978,0)
 ;;=L03.90^^76^992^30
 ;;^UTILITY(U,$J,358.3,22978,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22978,1,3,0)
 ;;=3^Cellulitis
 ;;^UTILITY(U,$J,358.3,22978,1,4,0)
 ;;=4^L03.90
 ;;^UTILITY(U,$J,358.3,22978,2)
 ;;=^5009067
 ;;^UTILITY(U,$J,358.3,22979,0)
 ;;=Z79.1^^76^992^31
 ;;^UTILITY(U,$J,358.3,22979,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22979,1,3,0)
 ;;=3^Long Term Use NSAID/Oth Health Status
 ;;^UTILITY(U,$J,358.3,22979,1,4,0)
 ;;=4^Z79.1
 ;;^UTILITY(U,$J,358.3,22979,2)
 ;;=^5063332
 ;;^UTILITY(U,$J,358.3,22980,0)
 ;;=Z79.899^^76^992^32
 ;;^UTILITY(U,$J,358.3,22980,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22980,1,3,0)
 ;;=3^Long Term Use Oth Drug
 ;;^UTILITY(U,$J,358.3,22980,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,22980,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,22981,0)
 ;;=Z80.8^^76^992^33
 ;;^UTILITY(U,$J,358.3,22981,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22981,1,3,0)
 ;;=3^Family Hx of Melanoma
 ;;^UTILITY(U,$J,358.3,22981,1,4,0)
 ;;=4^Z80.8
 ;;^UTILITY(U,$J,358.3,22981,2)
 ;;=^5063356
 ;;^UTILITY(U,$J,358.3,22982,0)
 ;;=Z48.817^^76^992^34
 ;;^UTILITY(U,$J,358.3,22982,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22982,1,3,0)
 ;;=3^Surgical Aftercare Skin/Subcutaneous Tissue
 ;;^UTILITY(U,$J,358.3,22982,1,4,0)
 ;;=4^Z48.817
 ;;^UTILITY(U,$J,358.3,22982,2)
 ;;=^5063054
 ;;^UTILITY(U,$J,358.3,22983,0)
 ;;=R99.^^76^992^35
 ;;^UTILITY(U,$J,358.3,22983,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22983,1,3,0)
 ;;=3^Dead Unknown Mortality
 ;;^UTILITY(U,$J,358.3,22983,1,4,0)
 ;;=4^R99.
 ;;^UTILITY(U,$J,358.3,22983,2)
 ;;=^5019750
 ;;^UTILITY(U,$J,358.3,22984,0)
 ;;=Z85.9^^76^992^36
 ;;^UTILITY(U,$J,358.3,22984,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22984,1,3,0)
 ;;=3^Personal Hx of Unspec Neoplasm/Cancer
 ;;^UTILITY(U,$J,358.3,22984,1,4,0)
 ;;=4^Z85.9
 ;;^UTILITY(U,$J,358.3,22984,2)
 ;;=^5063452
 ;;^UTILITY(U,$J,358.3,22985,0)
 ;;=C79.9^^76^992^37
 ;;^UTILITY(U,$J,358.3,22985,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22985,1,3,0)
 ;;=3^Metastatic Cancer Unspec
 ;;^UTILITY(U,$J,358.3,22985,1,4,0)
 ;;=4^C79.9
 ;;^UTILITY(U,$J,358.3,22985,2)
 ;;=^5133344
 ;;^UTILITY(U,$J,358.3,22986,0)
 ;;=Q3014^^77^993^1^^^^1
 ;;^UTILITY(U,$J,358.3,22986,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,22986,1,2,0)
 ;;=2^Q3014
 ;;^UTILITY(U,$J,358.3,22986,1,3,0)
 ;;=3^Telehealth Fac Fee-Pt Site
 ;;^UTILITY(U,$J,358.3,22987,0)
 ;;=B19.10^^78^994^1
 ;;^UTILITY(U,$J,358.3,22987,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,22987,1,3,0)
 ;;=3^Hepatitis B w/o Hepatic Coma
 ;;^UTILITY(U,$J,358.3,22987,1,4,0)
 ;;=4^B19.10
 ;;^UTILITY(U,$J,358.3,22987,2)
 ;;=^5000552
 ;;^UTILITY(U,$J,358.3,22988,0)
 ;;=B17.10^^78^994^2
